Literature DB >> 421237

Mechanism of the antimetastatic action of dimethyltriazenes.

G Sava, T Giraldi, L Lassiani, C Nisi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 421237

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

1.  Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative.

Authors:  M Allegrucci; P Fuschiotti; P Puccetti; L Romani; M C Fioretti
Journal:  Clin Exp Metastasis       Date:  1989 May-Jun       Impact factor: 5.150

2.  Antitumor and antimetastatic activity of the immunoadjuvant peptidoglycan monomer PGM in mice bearing MCa mammary carcinoma.

Authors:  G Sava; J Tomasic; I Hrsak
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Metabolism and pharmacokinetics of p-(3,3-dimethyl-1-triazeno) benzoic acid in M5076 sarcoma-bearing mice.

Authors:  E Benfenati; P Farina; T Colombo; G De Bellis; M V Capodiferro; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK.

Authors:  G Sava; S Zorzet; L Perissin; S Pacor; L Lassiani; C Nisi; A Varnavas
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Effects of prolonged treatment with decarbazine on tumor metastatic potential in mice bearing Lewis lung carcinoma.

Authors:  S Zorzet; L Perissin; V Rapozzi; S Pacor; T Giraldi
Journal:  Clin Exp Metastasis       Date:  1995-03       Impact factor: 5.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.